Meet The CEO(TM) Interviews BioBalance Corporation's CEO Mr. Dennis O'Donnell.

NEW YORK -- Meet The CEO(TM) ('MTC') announces the release of its April 7th interview with BioBalance Corporation's (OTCBB: BBAL) CEO, Mr. Dennis O'Donnell. The interview, conducted by MTC's Jennifer Gardiner and accessible at www.meettheceo.com, will be available beginning at 9:00 a.m. EST today through to October 2006.

The audio file is also available as a Podcast, enabling investors and interested parties to download the presentation to their desktop and/or any portable MP3 player.

About Meet The CEO(TM)

Meet The CEO(TM) provides a forum for domestic and international public and private companies, industry analysts and qualified financial professionals to inform the business and financial community of their business models, quarterly updates, corporate milestones or particular areas of expertise. The MTC environment affords corporate executives, and other specialized industry professionals, a platform to articulate their insights, goals and opinions beyond the standard Wall Street pitch. For further information, visit www.meettheceo.com or call 888-CEO-8899.

About BioBalance Corporation and New York Health Care, Inc

BioBalance Corporation, a development stage biopharmaceutical company, is focused on the development of innovative treatments for various gastrointestinal disorders that are poorly addressed by current therapies via accelerated regulatory pathways. These disorders include pouchitis, Irritable Bowel Syndrome (IBS), Crohn's disease, ulcerative colitis, C. difficile infections and antibiotic-associated diarrhea.

New York Health Care, Inc. (the "Company") and BioBalance completed a business combination on January 2, 2003, accounted for as a "reverse acquisition," in which BioBalance became a wholly owned subsidiary of the Company. The Company's common stock trades on the OTC Bulletin Board under the symbol BBAL. Additional information on BioBalance is located on the BioBalance website at www.biobalancecorp.com. Reports of the Company filed with the SEC are available on the SEC website at www.sec.gov.

SAFE HARBOR STATEMENT: In addition to historical information, certain of the statements in the preceding paragraphs, particularly those anticipating future events, financial performance, business prospects and growth and operating strategies constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as anticipate, believe, estimate, expect, intend, predict, hope or similar expressions. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements, including, without limitation, satisfaction of regulatory and other approvals and conditions necessary to market Probactrix(R), the Company's ability to implement its strategies and achieve its objectives and the risks and uncertainties described in reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation, the risk factors set forth and cautionary statements made in the Company's 2004 Annual Report on Form 10-K, as amended, its latest quarterly report on Form 10-Q and current reports on Form 8-K.

Consulting For Strategic Growth I, Ltd. ("CFSG") provides The BioBalance Corporation with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG receives a fixed monthly fee for the duration of the agreement. Independent of CFSG's receipt of cash compensation from BioBalance, CFSG may choose to purchase the common stock of New York Health Care, Inc. and thereafter sell those shares at any time it deems appropriate to do so.